The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation

Tomohiro Horio, Shohei Mizuno, Kaori Uchino, Motonori Mizutani, Ichiro Hanamura, J. Luis Espinoza, Makoto Onizuka, Koichi Kashiwase, Yasuo Morishima, Takahiro Fukuda, Yoshihisa Kodera, Noriko Doki, Koichi Miyamura, Takehiko Mori, Akiyoshi Takami

研究成果: Article

1 引用 (Scopus)

抄録

The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.

元の言語English
ジャーナルTransplant Immunology
DOI
出版物ステータスAccepted/In press - 2017 3 22

Fingerprint

Graft vs Host Disease
Bone Marrow Transplantation
Genotype
Transplants
Survival
Tissue Donors
Chemokine Receptors
Hematologic Neoplasms
Disease-Free Survival
Japan
Multivariate Analysis
Survival Rate
Bone Marrow
Inflammation
Recurrence
Mortality
Incidence
Neoplasms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Transplantation

これを引用

Horio, T., Mizuno, S., Uchino, K., Mizutani, M., Hanamura, I., Espinoza, J. L., ... Takami, A. (受理済み/印刷中). The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. Transplant Immunology. https://doi.org/10.1016/j.trim.2017.05.003

The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. / Horio, Tomohiro; Mizuno, Shohei; Uchino, Kaori; Mizutani, Motonori; Hanamura, Ichiro; Espinoza, J. Luis; Onizuka, Makoto; Kashiwase, Koichi; Morishima, Yasuo; Fukuda, Takahiro; Kodera, Yoshihisa; Doki, Noriko; Miyamura, Koichi; Mori, Takehiko; Takami, Akiyoshi.

:: Transplant Immunology, 22.03.2017.

研究成果: Article

Horio, T, Mizuno, S, Uchino, K, Mizutani, M, Hanamura, I, Espinoza, JL, Onizuka, M, Kashiwase, K, Morishima, Y, Fukuda, T, Kodera, Y, Doki, N, Miyamura, K, Mori, T & Takami, A 2017, 'The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation', Transplant Immunology. https://doi.org/10.1016/j.trim.2017.05.003
Horio, Tomohiro ; Mizuno, Shohei ; Uchino, Kaori ; Mizutani, Motonori ; Hanamura, Ichiro ; Espinoza, J. Luis ; Onizuka, Makoto ; Kashiwase, Koichi ; Morishima, Yasuo ; Fukuda, Takahiro ; Kodera, Yoshihisa ; Doki, Noriko ; Miyamura, Koichi ; Mori, Takehiko ; Takami, Akiyoshi. / The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. :: Transplant Immunology. 2017.
@article{b5c2be5d8839418c9d9c908bcfc5e293,
title = "The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation",
abstract = "The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.",
keywords = "Bone marrow transplantation, CCR5, Graft-versus-host disease, Single nucleotide variation, Unrelated donor",
author = "Tomohiro Horio and Shohei Mizuno and Kaori Uchino and Motonori Mizutani and Ichiro Hanamura and Espinoza, {J. Luis} and Makoto Onizuka and Koichi Kashiwase and Yasuo Morishima and Takahiro Fukuda and Yoshihisa Kodera and Noriko Doki and Koichi Miyamura and Takehiko Mori and Akiyoshi Takami",
year = "2017",
month = "3",
day = "22",
doi = "10.1016/j.trim.2017.05.003",
language = "English",
journal = "Transplant Immunology",
issn = "0966-3274",
publisher = "Elsevier",

}

TY - JOUR

T1 - The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation

AU - Horio, Tomohiro

AU - Mizuno, Shohei

AU - Uchino, Kaori

AU - Mizutani, Motonori

AU - Hanamura, Ichiro

AU - Espinoza, J. Luis

AU - Onizuka, Makoto

AU - Kashiwase, Koichi

AU - Morishima, Yasuo

AU - Fukuda, Takahiro

AU - Kodera, Yoshihisa

AU - Doki, Noriko

AU - Miyamura, Koichi

AU - Mori, Takehiko

AU - Takami, Akiyoshi

PY - 2017/3/22

Y1 - 2017/3/22

N2 - The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.

AB - The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.

KW - Bone marrow transplantation

KW - CCR5

KW - Graft-versus-host disease

KW - Single nucleotide variation

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=85019076279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019076279&partnerID=8YFLogxK

U2 - 10.1016/j.trim.2017.05.003

DO - 10.1016/j.trim.2017.05.003

M3 - Article

C2 - 28487238

AN - SCOPUS:85019076279

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

ER -